Comparative Pharmacology
Head-to-head clinical analysis: GANTRISIN versus MICROSUL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GANTRISIN versus MICROSUL.
GANTRISIN vs MICROSUL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive inhibitor of dihydropteroate synthase, blocking para-aminobenzoic acid (PABA) incorporation into dihydropteroic acid, thereby inhibiting bacterial folate synthesis and nucleic acid production.
MICROSUL inhibits bacterial dihydropteroate synthase, preventing folate synthesis, and also acts as a competitive antagonist of para-aminobenzoic acid (PABA).
2-4 g orally initially, then 4-8 g daily in 3-6 divided doses
Adult: 160 mg/800 mg (trimethoprim/sulfamethoxazole) orally every 12 hours for 14 days; intravenous dosing: 8-10 mg/kg/day (as trimethoprim) divided every 6, 8, or 12 hours.
None Documented
None Documented
7-12 hours (mean 10 hours); prolonged to 20-50 hours in renal impairment (CrCl <30 mL/min)
Terminal elimination half-life: 24-36 hours; prolonged in renal impairment
Renal: 70% as unchanged drug; hepatic metabolism: 30% as acetylated metabolites; biliary: <3%
Renal: 70% unchanged; biliary/fecal: 30% as metabolites
Category C
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic